Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hiroshi Ishiguchi is active.

Publication


Featured researches published by Hiroshi Ishiguchi.


Cancer Treatment Reviews | 2003

Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy

Hiroto Izumi; Takayuki Torigoe; Hiroshi Ishiguchi; Hidetaka Uramoto; Yoichiro Yoshida; Mizuho Tanabe; Tomoko Ise; Tadashi Murakami; Takeshi Yoshida; Minoru Nomoto; Kimitoshi Kohno

One of the major obstacles to the successful treatment of cancer is the complex biology of solid tumour development. Although regulation of intracellular pH has been shown to be critically important for many cellular functions, pH regulation has not been fully investigated in the field of cancer. It has, however, been shown that cellular pH is crucial for biological functions such as cell proliferation, invasion and metastasis, drug resistance and apoptosis. Hypoxic conditions are often observed during the development of solid tumours and lead to intracellular and extracellular acidosis. Cellular acidosis has been shown to be a trigger in the early phase of apoptosis and leads to activation of endonucleases inducing DNA fragmentation. To avoid intracellular acidification under such conditions, pH regulators are thought to be up-regulated in tumour cells. Four major types of pH regulator have been identified: the proton pump, the sodium-proton exchanger family (NHE), the bicarbonate transporter family (BCT) and the monocarboxylate transporter family (MCT). Here, we describe the structure and function of pH regulators expressed in tumour tissue. Understanding pH regulation in tumour cells may provide new ways of inducing tumour-specific apoptosis, thus aiding cancer chemotherapy.


Current Medicinal Chemistry - Anti-cancer Agents | 2005

Cisplatin Resistance and Transcription Factors

Takayuki Torigoe; Hiroto Izumi; Hiroshi Ishiguchi; Yoichiro Yoshida; Mizuho Tanabe; Takeshi Yoshida; Tomonori Igarashi; Ichiro Niina; Tetsuro Wakasugi; Takuya Imaizumi; Yasutomo Momii; Michihiko Kuwano; Kimitoshi Kohno

Cisplatin is one of the most potent and widely used anti-cancer agents in the treatment of various solid tumors. However, the development of resistance to cisplatin is a major obstacle in clinical treatment. Several mechanisms are thought to be involved in cisplatin resistance, including decreased intracellular drug accumulation, increased levels of cellular thiols, increased nucleotide excision-repair activity and decreased mismatch-repair activity. In general, the molecules responsible for each mechanism are upregulated in cisplatin-resistant cells; this indicates that the transcription factors activated in response to cisplatin might play crucial roles in drug resistance. It is known that the tumor-suppressor proteins p53 and p73, and the oncoprotein c-Myc, which function as transcription factors, influence cellular sensitivity to cisplatin. So far, we have identified several transcription factors involved in cisplatin resistance, including Y-box binding protein-1 (YB-1), CCAAT-binding transcription factor 2 (CTF2), activating transcription factor 4 (ATF4), zinc-finger factor 143 (ZNF143) and mitochondrial transcription factor A (mtTFA). Two of these-YB-1 and ZNF143-lack the high-mobility group (HMG) domain and can bind preferentially to cisplatin-modified DNA in addition to HMG domain proteins or DNA repair proteins, indicating that these transcription factors may also participate in DNA repair. In this review, we summarize the mechanisms of cisplatin resistance and focus on transcription factors involved in the genomic response to cisplatin.


Biochemical and Biophysical Research Communications | 2002

Human mitochondrial transcription factor A binds preferentially to oxidatively damaged DNA.

Yoichiro Yoshida; Hiroto Izumi; Tomoko Ise; Hidetaka Uramoto; Takayuki Torigoe; Hiroshi Ishiguchi; Tadashi Murakami; Mizuho Tanabe; Yoshifumi Nakayama; Hideaki Itoh; Hiroshi Kasai; Kimitoshi Kohno

Mitochondrial transcription factor A (mtTFA) is necessary for both transcription and maintenance of mtDNA, and is also one of the high mobility group (HMG) proteins that preferentially binds to cisplatin-damaged DNA. In this study we confirmed the preferential binding of mtTFA to cisplatin-damaged DNA, and also discovered that mtTFA binds to oxidatively damaged DNA. The affinity for oxidatively damaged DNA of mtTFA is higher for A/8-oxo-dG and C/8-oxo-dG than for G/8-oxo-dG and T/8-oxo-dG. Our findings suggest that mtTFA plays an important role in the recognition of oxidative DNA damage.


Anti-Cancer Drugs | 2002

Vacuolar H(+)-ATPase: functional mechanisms and potential as a target for cancer chemotherapy.

Takayuki Torigoe; Hiroto Izumi; Tomoko Ise; Tadashi Murakami; Hidetaka Uramoto; Hiroshi Ishiguchi; Yoichiro Yoshida; Mizuho Tanabe; Minoru Nomoto; Kimitoshi Kohno

Tumor cells in vivo often exist in a hypoxic microenvironment with a lower extracellular pH than that surrounding normal cells. Ability to upregulate proton extrusion may be important for tumor cell survival. Such microenvironmental factors may be involved in the development of resistant subpopulations of tumor cells. In solid tumors, both intracellular and extracellular pH differ between drug-sensitive and -resistant cells, and pH appears critical to the therapeutic effectiveness of anticancer agents. Four major types of pH regulators have been identified in tumor cells: the sodium–proton antiporter, the bicarbonate transporter, the proton–lactate symporter and proton pumps. Understanding mechanisms regulating tumor acidity opens up novel opportunities for cancer chemotherapy. In this minireview, we describe the structure and function of certain proton pumps overexpressed in many tumors—vacuolar H+-ATPases—and consider their potential as targets for cancer chemotherapy.


International Journal of Cancer | 2004

ZNF143 activates gene expression in response to DNA damage and binds to cisplatin-modified DNA

Hiroshi Ishiguchi; Hiroto Izumi; Takayuki Torigoe; Yoichiro Yoshida; Hiroshi Kubota; Sadatoshi Tsuji; Kimitoshi Kohno

We have identified a cisplatin‐inducible gene, the mitochondrial ribosomal protein S11 (MRP S11) gene, by means of mRNA differential display. Functional analysis of the MRP S11 promoter showed that a Staf binding site in the promoter is required for both basal promoter activity and cisplatin‐inducible activity. We also found that Staf binding activity is significantly increased in nuclear extracts from cells treated with cisplatin. ZNF 143 and ZNF 76 are human homologues of the Xenopus transcriptional activator, Staf. ZNF 143 expression is induced by cisplatin but ZNF 76 expression is not. However, ZNF 143 expression is not induced by transplatin, which is clinically ineffective. ZNF143 is an inducible gene by other DNA damaging agents such as γ‐irradiation, etoposide and adriamycin. ZNF 143 also binds preferentially to cisplatin‐modified DNA. These results suggest that ZNF 143 participates in cellular responses to DNA damage.


Oncogene | 2004

Binding of RNA to p53 regulates its oligomerization and DNA-binding activity

Yoichiro Yoshida; Hiroto Izumi; Takayuki Torigoe; Hiroshi Ishiguchi; Takeshi Yoshida; Hideaki Itoh; Kimitoshi Kohno

The C-terminus of p53 is responsible for maintaining the latent, non-DNA-binding form of p53. However, the mechanism by which the C-terminus regulates DNA binding is not yet fully understood. We show here that p53 interacts with RNA via its C-terminal domain and that disruption of this interaction, by RNase A treatment, truncation or phosphorylation of the C-terminus, restores DNA-binding activity. Furthermore, the oligomerization of p53 is significantly enhanced by disrupting the interaction between p53 and RNA. These findings suggest that binding of RNA to p53 is involved in the mechanism of p53 latency.


Supplements to Clinical neurophysiology | 2006

Mechanism of voluntary and involuntary movements in humans.

Sadatoshi Tsuji; Takenori Uozumi; Naoki Akamatsu; Akira Tamagawa; Kaoru Matsunaga; Hiroshi Ishiguchi; Tomoko Hashimoto; Yuki Kojima

Publisher Summary This chapter investigates the neurophysiological functions of primary negative motor area (area 44) in motor control, such as voluntary movements, studied by single-pulse transcranial magnetic stimulation (TMS) and subdural electrical stimulation. It also examines the relationship between cortical oscillatory activity and voluntary and involuntary hand movements in humans. To elucidate whether area 44 is essential for the organization of voluntary hand movements, the chapter examines the effects of single-pulse TMS of area 44 on voluntary hand movements and electromyographic (EMG) activity in hand muscles. The results show that magnetic and electrical stimulation of area 44 produced motor-evoked potentials (MEPs) from the hand muscles, but did not produce MEPs from the lower extremities. The chapter concludes that area 44 has direct fast-conducting corticospinal projections. Repetitive 50 Hz electrical stimulation of area 44 in the patients with intractable epilepsy induced disturbance of voluntary movements, tonic muscle contraction, and muscle weakness, which were similar to motor apraxia.


Cancer Research | 2003

p53 Physically Interacts with Mitochondrial Transcription Factor A and Differentially Regulates Binding to Damaged DNA

Yoichiro Yoshida; Hiroto Izumi; Takayuki Torigoe; Hiroshi Ishiguchi; Hideaki Itoh; Dongchon Kang; Kimitoshi Kohno


Nucleic Acids Research | 2001

Y box-binding protein-1 binds preferentially to single-stranded nucleic acids and exhibits 3′→5′ exonuclease activity

Hiroto Izumi; Toshihiro Imamura; Gunji Nagatani; Tomoko Ise; Tadashi Murakami; Hidetaka Uramoto; Takayuki Torigoe; Hiroshi Ishiguchi; Yoichiro Yoshida; Minoru Nomoto; Tatsuro Okamoto; Takeshi Uchiumi; Michihiko Kuwano; Keiko Funa; Kimitoshi Kohno


Journal of Biological Chemistry | 2002

Enhanced Expression of the Human Vacuolar H+-ATPase c subunit Gene (ATP6L) in Response to Anticancer Agents

Takayuki Torigoe; Hiroto Izumi; Hiroshi Ishiguchi; Hidetaka Uramoto; Tadashi Murakami; Tomoko Ise; Yoichiro Yoshida; Mizuho Tanabe; Minoru Nomoto; Hideaki Itoh; Kimitoshi Kohno

Collaboration


Dive into the Hiroshi Ishiguchi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Tomoko Ise

University of Gothenburg

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Minoru Nomoto

University of Occupational and Environmental Health Japan

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge